AP827A - Pharmaceutical preparation with trypanocidal qualities for veterinary use. - Google Patents
Pharmaceutical preparation with trypanocidal qualities for veterinary use. Download PDFInfo
- Publication number
- AP827A AP827A APAP/P/1998/001196A AP9801196A AP827A AP 827 A AP827 A AP 827A AP 9801196 A AP9801196 A AP 9801196A AP 827 A AP827 A AP 827A
- Authority
- AP
- ARIPO
- Prior art keywords
- volume
- pharmaceutical preparation
- preparation according
- water
- trypanocidal
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 18
- 230000000654 trypanocidal effect Effects 0.000 title claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 26
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229960004448 pentamidine Drugs 0.000 claims abstract description 10
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 9
- 229960005222 phenazone Drugs 0.000 claims abstract description 8
- 239000007864 aqueous solution Substances 0.000 claims abstract description 7
- 229920003086 cellulose ether Polymers 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 229950010741 aceturate Drugs 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 7
- 206010037660 Pyrexia Diseases 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 229920000609 methyl cellulose Polymers 0.000 claims description 4
- 239000001923 methylcellulose Substances 0.000 claims description 4
- 235000010981 methylcellulose Nutrition 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims description 3
- 229960004919 procaine Drugs 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 230000003444 anaesthetic effect Effects 0.000 claims 3
- 230000003119 painkilling effect Effects 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 abstract 1
- 229960005150 glycerol Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000013543 active substance Substances 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 3
- 201000008680 babesiosis Diseases 0.000 description 3
- 239000003139 biocide Substances 0.000 description 3
- 229940102223 injectable solution Drugs 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 239000002690 trypanocidal agent Substances 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- 229910052785 arsenic Inorganic materials 0.000 description 2
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 208000000230 African Trypanosomiasis Diseases 0.000 description 1
- 241000223836 Babesia Species 0.000 description 1
- 241000223840 Babesia bigemina Species 0.000 description 1
- 241000223846 Babesia canis Species 0.000 description 1
- 241000675161 Babesia motasi Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 241000324343 Causa Species 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- XNYZHCFCZNMTFY-UHFFFAOYSA-N diminazene Chemical compound C1=CC(C(=N)N)=CC=C1N\N=N\C1=CC=C(C(N)=N)C=C1 XNYZHCFCZNMTFY-UHFFFAOYSA-N 0.000 description 1
- 229950007095 diminazene Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 208000029080 human African trypanosomiasis Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 208000028172 protozoa infectious disease Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 201000002612 sleeping sickness Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 201000002311 trypanosomiasis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
A pharmaceutical composition with oypanccidal properties useful in veterinary medicine in' the form of an aqueous solution contain; diminazen-diacerurate. pentamidine, phenazon, glycerine and a water-soluble cellulose ether.
Description
Pharmaceutical preparation with trypanocidal qualities
Feld of application
The invention refers to a pharmaceutical preparation with trypanocidal qualities for veterinary medical use, in the form of an aqueous solution, which contains diminazen-di-aceturate (4.4’ diamidinediazobenzenediacelamidoacetate) and pentamidine (4.4’ - (pentamethyienedioxy) dibenzamidine) as trypanocidal drugs, phenazone (1.2- dihydro-1,5-dimethyi-2-phenyl-3Hpyrazo(e-3-one) as fever-reducing and pain-relieving components, as well as glycerol.
In countries with a tropica! climate, infectious diseases caused by protozoa are widely spread, such as the so-called sleeping sickness (trypanosomiasis), which damages the central nervous system and leads to death if not treated. The disease concerns humans and animals equally and has to be treated by chemotherapy.
In the field of agriculture, veterinary medicine is in great need of effective preparations to fight such infectious diseases. Permanent consideration needs to be paid to the fact that conditions in regard to sanitary measures as they can be found in Africa, for example, are oftentimes poor.
Prior art
Arsenic preparations and trypan dyes are known as chemotherapeutical drugs, which are, however, disadvantageous due io their content of arsenic respectively their carcinogenicity. A weH known preparation which has long been used for the treatment of such infections in animals in many cases is a trypanosome on the basis of diminazene powder. Other commercial trypanosomes are aiso available in a powdered form only. But especially the powdered form of the drug is extremely disadvantageous, due to the fact that the powdered drugs cannot be mixed into the fodder and thus need to be mixed with water to make an injectable solution. It Is not possible to produce a sterile solution from the powdered preparations, since the active substances form crystals in the solution after a short time, so that the effectiveness of the preparation gets lost quickly. Thus, such solutions cannot be stored and transported well enough. For this reason the injectable solution has to be produced a short time before the injection. This is very dangerous due to the fact that the water which is available, usually contains bacteria, viruses and causative organisms, which can causa additional
AP/P/ 9 8/01 196
AP 0 0 0 8 2 7 diseases in the animals and would thus put great strain on the animals. Also, no complete solution of the solids can be reached, due to poor solubility of these powdered drugs. This leads to an insufficient effectiveness of the injectable solution.
The powdered trypanosomes which are known today, thus pose a danger of additional infections respectively contamination. At the same time there is the danger of underdosage of the therapeutic drug, so that the chemotherapeutic treatment may have to be repeated, which naturally involves an increased risk of infections and the like.
In order to avoid the disadvantages of powdered trypanosomes, aqueous solutions of diminazen-di-aceturate have been developed, which contain caster oil as a solubiliser.
The manufacturing process is, however, relatively time-consuming and the stability of the resuiting solution of the preparation can only be assured up to a temperature of about 25*C.
This may be sufficient under normal circumstances; in tropical countries, however, storage conditions cannot always be observed, so that the preparation will spoil.
Problem, solution, advantages
The object of the invention is to provide a solution of a pharmaceutical preparation of the abovedescribed kind which remains stable, even in high temperatures.
in order to solve this problem, the plan according to the invention is to provide a \ pharmaceutical preparation with trypanocidal qualities in the form of an aqueous solution which contains the following agents:
(Ix » diminazen-di-aceturate (4.4’ diamidine-diazoaminobenzene-diacetamido-acetate) • pentamidine (4.4’-(pentamethylenedioxy)-dibenzamidine) • phenazone (1,2-dihydro-1,5-dimethyl-2-phenyl-3H-pyrazole-3-one) • glycerol • water-soluble cellulose ether.
AP/P/ 9 8/01 196
APΟ 0 Q q 2 γ
Diminazen-di-aceturats and pentamidine are trypanocidal drugs with different activity spectrums which therefore complement each ether in regard to their area of effectiveness, so that almost ail kinds of blood parasites can be treated. Additionally, this combination has the advantage of avoiding resistance.
An advantage of the combination of the two trypanocidal agents according to the invention is that the diminazen-di-aceturate’s poor water solubility is compensated by the pentamidine which is water-soluble and acts as a'solubiiiser.
Also, the phenazorse brings about a better solubility of the diminazen-di-aceturate besides its effectiveness as an analgesic with the advantage of alleviating pains and fevers in animals, caused by the injection respectively infection.
Glycerol and the water-soluble cellulose ether serve as emulsifiers; however, a stable aqueous solution can only be reached by a combination of all above mentioned agents, according to the invention.
Advantageously, the preparation according to the invention is stable enough to allow for the preparation to be heated up to 7Q°C for an extended period without showing any signs of disintegration.
Preferably, the water-soluble cellulose ether used is methyl cellulose, even though other cellulose ethers, such as hydroxy-ethyl-cellulbse or hydroxy-propyl-celiulose or any of their mixtures can also be used.
AP/P/ 9 8/01 196
The water is preferably a water which is physiologically, i.e. with regard to its pH and Its osmolarity, adapted. The water is pH-neutral and isotonic. Also, it contains 0.9 ± 0.3¾ of sodium chloride.
The result is an aqueous solution as a preparation, which keeps without problems, since the drug cannot crystallise. Moreover, there is no danger of an additional infection, since the preparation can be manufactured under sterile conditions.
The preparation according to the invention assures the effectiveness of the preparation against the following protozoa:
AP 0 0 0 8 2 7 • Trypanosomes congolense, Tryp. vivax, Tryp. Sruccei and T. Evartsi • Piroplasmosis (piroplasma motasi, piroplasma caballi) • Babesiosis (babesia bigemina, babesia motasi, babesia canis and other babesias) • Thaileria annulate.
According to another preferred embodiment, the preparation according to the invention is combined with another fever-reducing substance and/or a painkiller. This combination has the above-mentioned advantage of reducing the mortality rate of tha treated animals significantly by lowering the high fever which occurs together with a protozoal infection respectively reducing the strong pain in connection with the injection, which can lead to a fatal state of shock.
Lidocaine, procaine or any of their derivatives are preferably U3ed. If required, acetyl» licylic add can additionally be used against fever and as a painkiller.
According to another embodiment, the preparation according to the invention comprises isometadium-hydrochloride from the group of phenathridines as a further biocidal agent.
A preferred embodiment of the preparation according to the invention shows the following composition.
Active agents: diminazen-di-aceturate pentamidine phenazone lidocaine 33.5 % by volume
AP/P/ 9 8/01 196
Mixture of emulsifying agent and water: glycerol methyl cellulose physiologically adapted water 66.5 % by volume
The composition of active agents in % by weight is preferably the following:
| diminazen-di-aceturate | 20.9% |
| pentamidine | 11.9% |
| phenazone | 37.3 % |
| iidocaine | 29.9 % |
APOΟ Ο 8 2 7 and that of the mixture of emulsifier and water is the foilowing, in % by volume:
gtycerol 20.0 % methyi cellulose 1.6% physiologically adapted water 78.4 %
The preparation according to the invention offers the advantage that in relation to volume, the content of active agents can be doubled in comparison to the prior art.
Further advantages can be seen in the fact that by using the preparation according to tha invention, an extremely fast and complete cure wili be reached within 8 to 12 hours. At the same time, the preparation shows an increased effectiveness in comparison to other preparations, since ail protozoa can be effectively fought. Moreover, application can be carried out effortlessly, since the prescribed doses are smaller than those of other trypanocidal preparations, so that fewer treatments, sometimes one single injection of 15 mi, will be sufficient.
The fact that one single injection which is necessary for chemotherapy also provides protection from reinfection for three months has to be seen as a special advantage.
Another major advantage is to be seen in the fact that the required time for manufacturing can be drastically reduced in comparison to other preparations, since the components can simply be mixed by stirring, without being heated.
Further advantageous embodiments will be characterised in the dependent claims.
AP/F/ 9 8/01 196
APOΟ 0 8 2 7
Detailed description of the invention and best wav of carrying out the invention
Below, the invention will be more closely explained by means of an example.
A preferred embodiment of the pharmaceutical preparation can be prepared by mixing the biocidal agents, the intended further components which improve the effectiveness and the mixture of water and emulsifier.
in order to provide 3,35 grams of a mixture of biocidal agent and components which improve the effectiveness, the following will be mixed;
| 0.7 g | dimina2»n-di-aceturate |
| 0.4 g | pentamidine |
| 1.25g | phenazone and |
| 1.0 g | lidocain. |
Subsequently, the mixture of emulsifier and water, which consists of glycerol 20 % by volume, methyl cellulose 1.6 % by volume and physiological water 78,4 % by volume, will, be added to the active substances. The ready-for-use preparation can be filtered in a sterile way and drawn off.
The above-mentioned quantitative ratio has proved to be the most suitable, even though different ratios are also possible for the combination of substances according to the invention, so that an adaptation to the respective conditions is possible.
APT/ 9 8/01 196
AP000827
International Application PCT/EP 56/03657
Applicant: BOURDICHON, Aiain Jaques
Η.ινί,ιΰ now particularly described and ;fseeri;iined.niy/our said invention and in v luu manner the same is to be pertonneJ • /we declare that what J/we claim is-·
Claims (10)
- Claims1. A pharmaceutical preparation with trypanocidal qualities for veterinary medical use in the form of an aqueous solution, containing diminazen-die-aceturate (4,4'-pentadiacetamidoacetate) as trypanocidai drug, phenazone ft ,2-dihydro-1,5-dimetbyS-2-phenyl3H-pyrazole-3-one) as a fever-reducing and painkilling component as well as glycerol, characterised in that the preparation contains pentamidine (4.4'-(pentamethylendioxy)dibenzamidlne and a water soluble cellulose ether as a solubiliser.
- 2. A pharmaceutical preparation according to claim 1, characterised in that methyl cellulose is used as cellulose ether.
- 3. A pharmaceutical preparation according to claim 1 or 2, characterised in that the water that is used is physiologically adapted water, which has been adapted with regard to its pH and/or its osmolarity.
- 4. A pharmaceutical preparation according to claim 3, characterised in that the pH of the water is neutral.
- 5. Pharmaceutical preparation according to claim 3 or 4, characterised in that the water is isotonic and contains 0.9 ± 0.3 % of sodium chloride.5. A pharmaceutical preparation according to any of the claims 1 to 5, characterised in that it contains a local anaesthetic.
- 7. A pharmaceutical preparation according to claim 6, characterised in that lidocain or a lidocain derivative is used as local anaesthetic.AP/P/ 9 8/01 196APO 0 0 8 2 7
- 8.8.
- 9.9.
- 10.10.
- 11.11.A pharmaceutical preparation according to claim 6, characterised in that procaine or a procaine derivative is used as local anaesthetic.A pharmaceutical preparation according to any of the claims 1 to 7, characterised in that it contains 15 to 40 % by volume - preferably 33.5 % by volume - of a trypanocidal drug and a painkilling and fever-reducing component, wherein 15 to 25 % by volume preferably 20.9 % by volume - of diminazen-di-aceturate, 7 to 20 % by volume preferably 11.9 % by volume - of pentamidine, 20 to 45 % by volume - preferably 37.3 % by volume - of phenazone and 15 to 45 % by volume - preferably 29.9 %' by volume - of lidocain are contained, and 60 to 85 % by volume - preferably 66.5 % by volume - of glycerol, cellulose polymer and water, wherein 15 to 30 % by volume - preferably 20 % by volume - of glycerol, 1 to 3 % by volume - preferably 1.6 % by volume - of cellulose polymer and 70 to 80 % by volume - preferably 78.4 % by volume - of water are contained.A pharmaceutical preparation according to any of the claims 1 to 9, characterised in that the,pharmaceutical preparation contains acetylsalicylic acid.Pharmaceutical preparation according to any of the claims 1 to 10, characterised in that isometadium-hydrochloride from the group of phenathridines is contained.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1995130708 DE19530708C2 (en) | 1995-08-21 | 1995-08-21 | Pharmaceutical preparation with trypanocidal properties |
| PCT/EP1996/003657 WO1997006769A2 (en) | 1995-08-21 | 1996-08-20 | Pharmaceutical composition with trypanocidal properties |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP9801196A0 AP9801196A0 (en) | 1998-03-31 |
| AP827A true AP827A (en) | 2000-04-28 |
Family
ID=7769997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/1998/001196A AP827A (en) | 1995-08-21 | 1996-08-20 | Pharmaceutical preparation with trypanocidal qualities for veterinary use. |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0845983A2 (en) |
| AP (1) | AP827A (en) |
| AU (1) | AU6875096A (en) |
| DE (1) | DE19530708C2 (en) |
| EA (1) | EA199800218A1 (en) |
| OA (1) | OA10665A (en) |
| WO (1) | WO1997006769A2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE29618094U1 (en) * | 1996-10-18 | 1998-02-12 | Bourdichon, Alain Jaques, 22301 Hamburg | Pharmaceutical preparation |
| DE19853937A1 (en) * | 1998-11-24 | 2000-05-25 | Chambord Ltd | Composition useful for treating e.g. malaria, babesiosis and trypanosomiasis comprises diminazene diaceturate and procaine |
| DE10325672A1 (en) * | 2003-06-03 | 2004-12-23 | Tropmed Gmbh | Pharmaceutical preparation for the treatment of tropical parasitic diseases |
| CN105168121A (en) * | 2015-08-28 | 2015-12-23 | 重庆布尔动物药业有限公司 | Diminazene compound for veterinary use and preparation method of diminazene compound |
| RU2638433C1 (en) * | 2016-12-15 | 2017-12-13 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Горский государственный аграрный университет" | Method for increast of therapeutic efficiency of diminasin-70 in case of cattle pyroplasmosis |
| RU2638444C1 (en) * | 2016-12-15 | 2017-12-13 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Горский государственный аграрный университет" | Method of increasing medical efficiency for cattle pyroplasmosis with neozidin-m in association with laserpuncture |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4309415A1 (en) * | 1993-03-19 | 1994-09-22 | Alan Jacques Bourdichon | Pharmaceutical product |
-
1995
- 1995-08-21 DE DE1995130708 patent/DE19530708C2/en not_active Expired - Fee Related
-
1996
- 1996-08-20 EA EA199800218A patent/EA199800218A1/en unknown
- 1996-08-20 EP EP96929285A patent/EP0845983A2/en not_active Ceased
- 1996-08-20 WO PCT/EP1996/003657 patent/WO1997006769A2/en not_active Ceased
- 1996-08-20 AP APAP/P/1998/001196A patent/AP827A/en active
- 1996-08-20 AU AU68750/96A patent/AU6875096A/en not_active Abandoned
-
1998
- 1998-02-20 OA OA9800022A patent/OA10665A/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4309415A1 (en) * | 1993-03-19 | 1994-09-22 | Alan Jacques Bourdichon | Pharmaceutical product |
Also Published As
| Publication number | Publication date |
|---|---|
| DE19530708C2 (en) | 1999-01-07 |
| WO1997006769A2 (en) | 1997-02-27 |
| EA199800218A1 (en) | 1998-12-24 |
| DE19530708A1 (en) | 1997-02-27 |
| EP0845983A2 (en) | 1998-06-10 |
| AU6875096A (en) | 1997-03-12 |
| AP9801196A0 (en) | 1998-03-31 |
| OA10665A (en) | 2002-09-25 |
| WO1997006769A3 (en) | 1997-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2292233T3 (en) | COMPOSITION OF PROPOFOL CONTAINING SULPHITE. | |
| Benish et al. | Perioperative use of β-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis | |
| JP3925900B2 (en) | Long-acting injection containing hydrogenated castor oil | |
| Turner et al. | Pharmacokinetics of meloxicam in rabbits after single and repeat oral dosing | |
| US4604391A (en) | Treatment of osteitis and osteomyelitis employing thiadiazine compounds | |
| US4520014A (en) | Treatment of diarrhoea | |
| SK124797A3 (en) | Oil in water emulsions containing propofol and edetate | |
| AP827A (en) | Pharmaceutical preparation with trypanocidal qualities for veterinary use. | |
| KR930003915A (en) | Medications for rejection response to organ transplantation | |
| PT1879654E (en) | PHARMACEUTICAL COMBINATION COMPOSING AN ANTIFUNGAL AGENT AND AN ACTIVE SUBSTANCE ESPECIALLY SELECTED BETWEEN EUGENOL AND CARVACROL | |
| Bullard et al. | Comparison of intravenous versus intracarotid therapy with 1, 3-bis (2-chloroethyl)-1-nitrosourea in a rat brain tumor model | |
| JPH064534B2 (en) | Combination drug for long-term pain relief | |
| TW201043231A (en) | Blood parasiticide | |
| JP5981430B2 (en) | Composition for treating Hartworm infection | |
| JPS59205321A (en) | Anthelmintic synergistical novel composition | |
| US6110971A (en) | Fungicide composition comprising a benzoylphenylurea | |
| US4912138A (en) | Pharmaceutical preparation containing thiamphenicol for veterinary use | |
| CN109431999A (en) | A kind of nano-self-microemulsion agent, veterinary drug nano-self-microemulsion agent and the preparation method and application thereof | |
| KR100645268B1 (en) | Pharmaceutical Compositions for Veterinary Medicine | |
| CN100457086C (en) | sterile pharmaceutical composition | |
| US20120021067A1 (en) | Maintenance fluid for animals | |
| CN121059577A (en) | Application of naphthoquinone compound in preventing and/or treating parasitic diseases in aquatic animals | |
| TWI246927B (en) | One kind of concentrated emulsion containing Paclitaxel (taxane) | |
| RU1751890C (en) | Romixin preparation for treating calf colibacillosis | |
| CZ300146B6 (en) | Sterile, aqueous composition containing oil-in-water emulsion and edetate |